Korro Bio, Inc.

KRRO

Healthcare Biotechnology

Korro Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, up 181.5% from fiscal 2024.

Revenue
−86.3%
EPS
+61.0%
Free cash flow
+12.1%

Quarter to June 2026, against a year earlier

14.75 0.02 +0.14%
Market cap
$202.5M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
0.6×
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17
Total current assets
82.37 131.53 172.73 57.08 134.75 225.06 221.36 42.94 17.96
Total non-current assets
31.13 94.71 48.94 16.66 50.61 39.66 1.86 1.61 —
Total Assets
113.51 226.24 221.66 73.74 185.36 264.72 223.22 44.55 —
Total current liabilities
11.94 14.96 19.48 8.70 11.43 26.63 52.78 3.77 2.23
Total non-current liabilities
50.13 50.87 32.27 0.21 43.11 45.60 3.08 0.35 —
Total liabilities
62.07 65.83 51.75 8.91 54.53 72.23 55.86 4.12 —
Common Equity (Total)
51.44 160.42 169.91 (99.03) 130.82 192.49 167.36 (44.51) (29.64)
Shareholders Equity (Total)
51.44 160.42 169.91 64.83 130.82 192.49 167.36 40.43 —
Total Debt
— — — 14.17 15.00 15.40 — 84.94 46.69

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 26 Oct 2026